Colorado Drug Price Cap Faces Amgen Lawsuit in Court

The Colorado Sun’s John Ingold reports that Amgen is in federal court trying to block Colorado’s first-in-the-nation cap on the price of Enbrel, a prescription drug used to treat rheumatoid arthritis and other autoimmune diseases. The cap was imposed by Colorado’s Prescription Drug Affordability Board, a state board created in 2021 to review expensive drugs, declare them unaffordable when warranted, and limit what patients or insurers must pay for them in Colorado.

This is Colorado first stuff. The state built a shiny new drug-price-capping machine, and now Amgen is trying to drag it into court before it becomes a national model. This is not abstract “health policy.” This is sick people, families, employers, and taxpayers getting financially clubbed while pharma lawyers and state technocrats fight over who gets to hold the wrench.

The best line came from Chief Judge Daniel Domenico, who, after trying to sort through wholesalers, pharmacy benefit managers, rebates, chargebacks, and pricing sludge, asked Amgen’s attorney: “Why is it such a mess?” Exactly. That is the whole damn health care system in five words.

The Bullet Point Brief

• Colorado’s Prescription Drug Affordability Board voted last year to cap the price of Enbrel, which The Sun reports brought in more than $2.2 billion worldwide for Amgen last year. Amgen is now suing to overturn the cap before it takes effect next year. Everyone says they care about affordability until somebody touches the money.
• Amgen argues the cap interferes with federal patent law, which gives drug companies an exclusive window to sell products as a reward for research and development. Fine, innovation matters. But “innovation” cannot be a magic spell that turns every patient into an ATM with arthritis.
• The state argues the cap is technically an upper payment limit on what the end purchaser pays, not a direct cap on what Amgen charges. The judge asked who actually loses money in that chain, and the state said it was unclear because pharmaceutical pricing behaves in counterintuitive ways. Translation: the system is so stupid even the courtroom needed a map and a snack.
• The Sun notes that Colorado’s board focused on drugs without cheaper generic alternatives, which is why Enbrel was targeted and Humira was not. That gets to the heart of the racket: patent protection, no generic escape hatch, complicated pricing, and patients left standing at the counter wondering why medicine now requires a hostage negotiator.
• Colorado’s political class gets a side-eye too. Polis and legislative Democrats built this board and want credit for affordability. Good. Now prove it works. Does this cap actually help patients, employers, and taxpayers, or does it become another task-force piñata stuffed with press releases, legal bills, and acronyms?

My Bottom Line

Amgen does not get to play the innocent victim here. Enbrel is a major money-maker, and when Colorado tried to cap what people have to pay, the lawyers came out. That is not shocking. That is the business model protecting itself with a briefcase.

But Colorado government does not get a halo either. A government board is not automatically heroic just because it has “affordability” in the title. Colorado has a long habit of building bureaucratic contraptions, holding a press conference, and then acting surprised when the gears jam, the lawyers swarm, and regular people still get the bill.

The real scandal is that medicine affordability in America requires a bureaucratic knife fight at all. The normal market has been replaced by patent games, insurance sludge, rebates, middlemen, lobbyists, and everyone pretending the patient is the customer while treating them like a blinking debit card in a hospital gown.

So yes, scrutinize Amgen. Hard. But also demand that Colorado prove this board is more than another progressive health policy experiment wandering into court with a binder and a dream. If the cap lowers costs for sick people, good. If it just launches a courtroom circus while patients keep paying through the nose, then it is another Colorado affordability promise with nice lighting and no landing gear.

Everyone says they care about affordability until somebody touches the money. That is when the lobbyists come out like raccoons in a dumpster behind the Capitol.

Source: The Colorado Sun